• Completed

NCT00833560: Phase 2: A Study of Bortezomib, Cyclophosphamide, and Dexamethasone in Patients NDMM

Updated: Jun 22

German DSMM Xia trial

German DSMM Xia trial

NCT00833560: Phase 2: A Study of Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Untreated Multiple Myeloma and Planned for a High Dose Chemotherapy



A Study of Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Untreated Multiple Myeloma and Planned for a High Dose Chemotherapy.


The purpose of this study is to evaluate the safety and effectiveness of bortezomib in combination with a standard regimen of cyclophosphamide and dexamethasone.


Sponsor:

Janssen-Cilag G.m.b.H


Location: Germany


ClinicalTrials.gov Identifier: NCT00833560


Official Title: Clinical Study on Induction of Remission Using Bortezomib (Vel), Cyclophosphamide (C), and Dexamethasone (D) in Patients Until 60 Years of Age With Untreated Multiple Myeloma and Planned for a High Dose Chemotherapy: (VelCD; Deutsche Studiengruppe Multiples Myelom [DSMM] XIa)

First Posted : February 2, 2009


Click here to see details on ClinicalTrials.gov

 

Bortezomib : National Cancer Institute

Bortezomib : MedlinePlus Drug Information

Dexamethasone : National Cancer Institute

Dexamethasone : MedlinePlus Drug Information


Cyclophosphamide : National Cancer Institute

Cyclophosphamide : MedlinePlus Drug Information

Cyclophosphamide IV : MedlinePlus Drug Information

 

Drug: Cyclophosphamide

Drug: Bortezomib

Drug: Dexamethasone

 

Responsible Party:

Janssen-Cilag G.m.b.H


26866138MMY2031

2005-003902-27 ( EudraCT Number )

 

Meeting Abstract | 2009 ASCO Annual Meeting

Bortezomib, IV cyclophosphamide, and dexamethasone (VelCD) as induction therapy in newly diagnosed multiple myeloma: Results of an interim analysis of the German DSMM Xia trial


Conclusions: This interim analysis demonstrates that bortezomib combined with dexamethasone and intravenous cyclophosphamide (VelCD) is a highly effective induction regimen for pts ≤ 60 years with newly diagnosed MM regardless of cytogenetic risk factors

https://ascopubs.org/doi/abs/10.1200/jco.2009.27.15_suppl.8516

 

Br J Haematol; 2017

Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: DSMM XI trial

VCD is an effective and tolerable induction regimen; results suggest that VCD induces high response rates independently of cytogenetic risk status, but after long-term follow-up, cytogenetic high risk is associated with markedly reduced PFS and OS post-ASCT.

https://pubmed.ncbi.nlm.nih.gov/28961309/


Posts Archive